A case report on comorbidities and laboratory abnormalities of Telbivudine in Hepatitis B patients

About Authors:
1 School of Pharmaceutical Sciences,
Jaipur National University, Jaipur -302025, (Rajasthan.), India
2 institute of kidney disease and research center,
Civil hospital, Ahmedabad (Gujarat), India

Inpresent study, comorbidities and laboratory abnormalities of telbivudine was analysed in hepatitis b patients. Clinical data were collected from hepatitis b patients that presented with laboratory abnormalities to telbivudine. We examined 100 patients of hepatitis b  who treated with telbivudine in i.k.d.r.c, civil hospital, Ahmedabad from January 2009 to February 2011, out of these twenty patients had used other nucleoside analogue in past. The main laboratory abnormalities were elevation of creatine kinase, elevation of ALT and elevation of AST. Hypertension was the major comorbidities with the hepatitis b.The laboratory abnormalities were related to telbivudine, but the biological mechanism of the reaction is not clear.


About Authors: * Ryali. Jithendra, Dinesh Kumar. Pandurangan, Bandaru. Sowjanya1, Vijayaraj Kumar. Perumal2
1Department of Biotechnology, Acharya Nagarjuna University, Guntur – 522 510, India,
*1-Department of Pharmaceutics, Rahul Institute of Pharmaceutical Science & Research, Chirala-523157, Andhra Pradesh, India.
2-School of Pharmacy, University College Sadaya International,Kuala Lumpur, Malaysia.

Pharmacovigilance is an important and integral part of clinical research. Pharmacovigilance is “defined as the pharmacological science relating to the detection, assessment, understanding and prevention of adverse effects, particularly long term and short term adverse effects of medicines. This addresses what exactly is pharmacovigilance?  What do we know of its benefits and risks, challenges and the future hold for pharmacovigilance in Indian medicine. Here the main focus on the aims and role of pharmacovigilance in medicines regulation and their Partners. This article describes and discusses the National programme of pharmacovigilance and centre in India. There role in collecting the reports ADRs of medicines. Further effectiveness and risk assessments of therapies are been discussed. The important role played by health care professional, pharmaceutical industries, media, and programmes carried by WHO. Finally the conclusion describes the major challenges and achievements for the future pharmacovigilance programme.

Job as Pharmacovigilance Expert (Drug Safety and Epidemiology) in Novartis Healthcare

A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

Work in Medical Writing - Pharmacovigilance @ J. B. Chemicals & Pharmaceuticals Ltd.

J. B. Chemicals & Pharmaceuticals Ltd. (JBCPL), known to many as Unique Pharmaceutical Laboratories is one of India's leading global pharmaceutical companies. The company manufactures and markets a wide range of pharmaceutical formulations.

Post:  Medical Writing - Pharmacovigilance

Recession hit West storms into India for clinical research, pharmacovigilance next growth path for CROs

 India’s clinical research organizations (CROs) are set for exponential growth going by the number of assignments which are coming in here. The global economic slowdown which has seriously impacted western world has benefited the Indian clinical research industry. Scores of assignments are pouring in to conduct clinical trials, pharmacovigilance studies and data management works.

Several drugs to come under regulatory scanner as national pharmacovigilance programme to begin in April

Two H1N1 drugs - oseltamivir and zanamavir, the controversial sub-fertility drug letrozole, popular non-steroidal anti-inflammatory drug nimesulide, decongestant drug phenylpropanolamine (PPA), antibiotic drug gatifloxacine, chronic constipation drug tegaserod, type-2 diabetes drug pioglitazone and rosiglitazone have been selected for the first phase of national pharmacovigilance programme which will begin in select 40 medical colleges across the country from April this year.